TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis

Company Overview

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.07 to $0.07
• 52-Week Range: $0.06 to $11.00
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $288,795.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Buy

TFF Pharmaceuticals Stock Analysis - MarketRank™

TFF Pharmaceuticals scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TFF Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TFF Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TFF Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TFF Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TFF Pharmaceuticals has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TFFP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TFF Pharmaceuticals does not currently pay a dividend.

Dividend Growth

TFF Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TFFP.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for TFF Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TFF Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of TFF Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 15.25% of the stock of TFF Pharmaceuticals is held by institutions.

TFFP Stock Analysis - Frequently Asked Questions

How have TFFP shares performed this year?

TFF Pharmaceuticals' stock was trading at $0.0650 at the beginning of the year. Since then, TFFP shares have increased by 0.0% and is now trading at $0.0650.
View the best growth stocks for 2025 here.

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) posted its quarterly earnings results on Wednesday, November, 20th. The company reported ($0.81) EPS for the quarter. TFF Pharmaceuticals had a negative net margin of 1,596.64% and a negative trailing twelve-month return on equity of 310.17%.

When did TFF Pharmaceuticals' stock split?

TFF Pharmaceuticals shares reverse split on Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did TFF Pharmaceuticals IPO?

TFF Pharmaceuticals (TFFP) raised $22 million in an IPO on Friday, October 25th 2019. The company issued 4,400,000 shares at a price of $5.00 per share. National Securities served as the underwriter for the IPO.

Who are TFF Pharmaceuticals' major shareholders?

Top institutional investors of TFF Pharmaceuticals include Concourse Financial Group Securities Inc.. Insiders that own company stock include Carlson Capital L P, Harlan F Weisman, Aaron GL Fletcher, Zamaneh Mikhak, Stephen Rocamboli, Glenn R Mattes, Kirk Allen Coleman and Randy H Thurman.
View institutional ownership trends.

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TFF Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), General Electric (GE), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/20/2024
• Today: 3/09/2025
• Next Earnings (Estimated): 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TFFP
• CIK: 1733413
• Web: www.tffpharma.com
• Phone: 817-438-6168
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $44.00
• High Stock Price Target: $44.00
• Low Stock Price Target: $44.00
• Potential Upside/Downside: +67,592.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,240,000.00
• Net Margins: -1,596.64%
• Pretax Margin: -1,596.72%
• Return on Equity: -310.17%
• Return on Assets: -196.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.89
• Quick Ratio: 0.89

Sales & Book Value

• Annual Sales: $-70,983.00
• Price / Sales: -4.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 4,443,000
• Free Float: 4,244,000
• Market Cap: $288,795.00
• Optionable: Optionable
• Beta: 1.07